The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to litifilimab (BIIB059), an investigational monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), for the treatment of cutaneous lupus erythematosus (CLE).
Announced by Biogen on January 28, 2026, the designation is intended to expedite the clinical development and review of therapies for serious conditions when preliminary clinical evidence suggests potential for substantial improvement over existing treatments.
Key Drug Facts
Drug: Litifilimab (BIIB059), humanized IgG1 monoclonal antibody targeting BDCA2
Indication: Investigational for cutaneous lupus erythematosus (CLE)
Development Phase: Breakthrough Therapy Designation (FDA); Phase III AMETHYST ongoing
Key Efficacy: Phase II LILAC trial demonstrated CLASI-A improvement vs placebo at 16 weeks⁷
Safety Signals: Hypersensitivity reactions, herpesvirus infections reported in phase II⁷
Regulatory Status: Not approved; Breakthrough Therapy Designation in US as of 01/28/26
"The breakthrough therapy designation for litifilimab illustrates the FDA’s recognition of cutaneous lupus as a serious disease that urgently requires new therapies," said Victoria Werth, MD, MS, a professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, and one of the researchers who is conducting the phase 3 trial.1 "With topical steroids and antimalarials as the initial therapies for managing CLE and no alternatives specifically approved for CLE, there is a need for effective, targeted treatments, and that could be a drug like litifilimab.”
Cutaneous lupus manifests as photosensitive plaques, rash, pruritus, and potential scarring; it can occur with or without concurrent systemic lupus erythematosus (SLE) and is associated with impaired quality of life and psychosocial burden.2,3,4 Standard management for CLE continues to rely on topical corticosteroids, antimalarial agents (eg, hydroxychloroquine), and nonspecific immunosuppressants, but these approaches are limited by variable efficacy and safety concerns.5,6,7
The FDA’s breakthrough designation for litifilimab reflects phase II clinical data from the LILAC study showing reductions in skin disease activity compared with placebo. In this randomized, double-blind, placebo-controlled trial, subcutaneous litifilimab administered in multiple dose levels demonstrated superior efficacy versus placebo in the primary endpoint, measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) at week 16. Despite these promising signals, most secondary endpoints were not formally supportive, and the trial was not powered for longer-term outcomes or comprehensive safety characterization.8 The designation also aligns with the FDA’s recognition of CLE as a serious and debilitating condition with high unmet need.
Study Overview and Key Findings
The LILAC trial enrolled adults with histologically confirmed moderate-to-severe CLE, with or without systemic involvement. Participants received subcutaneous litifilimab (50 mg, 150 mg, or 450 mg) or placebo over 16 weeks, with dosing at weeks 0, 2, 4, 8, and 12. The primary analysis applied a dose-response model across treatment arms.8
At week 16, litifilimab showed a statistically significant improvement in the primary outcome of CLASI-A reduction compared with placebo, suggesting attenuation of cutaneous disease activity. Safety assessments identified instances of hypersensitivity and herpesvirus infections among litifilimab-treated patients, consistent with immunomodulatory therapy.8 Although supportive of activity, these results require confirmation in larger, adequately powered phase III studies with longer follow-up.
